Unlocking the treasure trove: From genes to schizophrenia biology

Schizophrenia Bulletin

Volumn 40, Issue 3, 2014, Pages 492-496

  McCarthy, Shane E ^a   McCombie, W Richard ^a   Corvin, Aiden ^b  

^a Stanley Institute of Cognitive Genomics Cold Spring Harbor Laboratory ^*  (United States)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

CRISPR; genomics; model; schizophrenia; sequencing; systems

Indexed keywords

ARTICLE; GENE; GENE FUNCTION; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SEQUENCE ANALYSIS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DNA SEQUENCE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; PHENOTYPE;

CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; PHENOTYPE; SCHIZOPHRENIA; SEQUENCE ANALYSIS, DNA;

EID: 84898999850     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbu042     Document Type: Article

References (51)

1. Corvin A. Schizophrenia at a genetics crossroads: Where to now? Schizophr Bull. 2013;39:490-495.
2. Ripke S, Sanders AR, Kendler KS, et al. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011;43:969-976.
3. Ripke S, O'Dushlaine C, Chambert K, et al.; Multicenter Genetic Studies of Schizophrenia Consortium; Psychosis Endophenotypes International Consortium; Wellcome Trust Case Control Consortium 2. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet. 2013;45:1150-1159.
4. Genetic Microsurgery for the Masses. Science. 2013; 342:1434-1435.
5. Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819-823.
6. Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823-826.
7. Cross Disorder Group of the Psychiatric Genomics COnsortium; Less SH, Ripke S, et al. Genetic relationships between five psychiatric disorders estimated from genomewide SNPs. Nat Genet. 2013;45:984-994.
8. Lappalainen T, Sammeth M, Friedländer MR, et al.; Geuvadis Consortium; Geuvadis Consortium. Transcriptome and genome sequencing uncovers functional variation in humans. Nature. 2013;501:506-511.
9. Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-Associated variation in regulatory DNA. Science. 2012;337:1190-1195.
10. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12:581-594.
11. Karayiorgou M, Flint J, Gogos JA, Malenka RC; Genetic and Neural Complexity in Psychiatry 2011 Working Group. The best of times, the worst of times for psychiatric disease. Nat Neurosci. 2012;15:811-812.
12. Tye KM, Mirzabekov JJ, Warden MR, et al. Dopamine neurons modulate neural encoding and expression of depressionrelated behaviour. Nature. 2013;493:537-541.
13. Kirov G, Rujescu D, Ingason A, Collier DA, O'Donovan MC, Owen MJ. Neurexin 1 (NRXN1) deletions in schizophrenia. Schizophr Bull. 2009;35:851-854.
14. Vacic V, McCarthy S, Malhotra D, et al. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature. 2011;471:499-503.
15. Levinson DF, Duan J, Oh S, et al. Copy number variants in schizophrenia: Confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry. 2011;168:302-316.
16. Stoll G, Pietildinen OP, Linder B, et al. Deletion of TOP3β, a component of FMRP-containing mRNPs, contributes to neurodevelopmental disorders. Nat Neurosci. 2013;16:1228-1237.
17. Morris DW, Pearson RD, Cormican P, et al. An inherited duplication at the gnee p21 Protein-Activated Kinase 7 (PAK7) is a risk factor for psychosis. [published online ahead of print March 9, 2014]. Hum Mol Genet.
18. Kirov G, Rees E, Walters JT, et al. The penetrance of copy number variations for schizophrenia and developmental delay. Biol Psychiatry. 2014;75:378-385.
19. Stefansson H, Meyer-Lindenberg A, Steinberg S, et al. CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nature. 2014;505:361-366.
20. Purcell SM, Moran JL, Fromer M, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;506:185-190.
21. Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506:179-184.
22. Need AC, McEvoy JP, Gennarelli M, et al. Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia. Am J Hum Genet. 2012;91:303-312.
23. Iossifov I, Ronemus M, Levy D, et al. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012;74:285-299.
24. Neale BM, Kou Y, Liu L, et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature. 2012;485:242-245.
25. O'Roak BJ, Vives L, Girirajan S, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012;485:246-250.
26. Vissers LE, de Ligt J, Gilissen C, et al. A de novo paradigm for mental retardation. Nat Genet. 2010;42:1109-1112.
27. Parikshak NN, Luo R, Zhang A, et al. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell. 2013;155:1008-1021.
28. Kirov G, Pocklington AJ, Holmans P, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry. 2012;17:142-153.
29. Cross Disorder Group of the Psychiatric Genomics Consortium, Genetic Risk Outcome of Psychosis (GROUP) Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: A genome-wide analysis. Lancet. 2013;381:1371-1379.
30. Xu B, Roos JL, Dexheimer P, et al. Exome sequencing supports a de novo mutational paradigm for schizophrenia. Nat Genet. 2011;43:864-868.
31. Xu B, Ionita-Laza I, Roos JL, et al. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat Genet. 2012;44:1365-1369.
32. Sanders SJ, Murtha MT, Gupta AR, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature. 2012;485:237-241.
33. de Ligt J, Willemsen MH, van Bon BW, et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med. 2012;367:1921-1929.
34. Rauch A, Wieczorek D, Graf E, et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: An exome sequencing study. Lancet. 2012;380:1674-1682.
35. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet. 2013;9:e1003709.
36. Epi4K Consortium; Epilepsy Phenome/Genome Project; Allen AS, Berkovic SF, Cossette P, et al. De novo mutations in epileptic encephaolopathies. Nature. 2013;501:217-221.
37. Steinberg J, Webber C. The roles of FMRP-regulated genes in autism spectrum disorder: Single-And multiple-hit genetic etiologies. Am J Hum Genet. 2013;93:825-839.
38. Voineagu I, Wang X, Johnston P, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature. 2011;474:380-384.
39. Gilman SR, Chang J, Xu B, et al. Diverse types of genetic variation converge on functional gene networks involved in schizophrenia. Nat Neurosci. 2012;15:1723-1728.
40. Gulsuner S, Walsh T, Watts AC, et al.; Consortium on the Genetics of Schizophrenia (COGS); PAARTNERS Study Group. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell. 2013;154:518-529.
41. Burne T, Scott E, van Swinderen B, et al. Big ideas for small brains: What can psychiatry learn from worms, flies, bees and fish? Mol Psychiatry. 2011;16:7-16.
42. Sawa A. Genetic animal models for schizophrenia: Advantages and limitations of genetic manipulation in drosophila, zebrafish, rodents, and primates. Prog Brain Res. 2009;179:3-6.
43. Bessa C, Maciel P, Rodrigues AJ. Using C. elegans to decipher the cellular and molecular mechanisms underlying neurodevelopmental disorders. Mol Neurobiol. 2013;48:465-489.
44. Smith CJ, Watson JD, Spencer WC, et al. Time-lapse imaging and cell-specific expression profiling reveal dynamic branching and molecular determinants of a multi-dendritic nociceptor in C. elegans. Dev Biol. 2010;345:18-33.
45. Tran NN, Ladran IG, Brennand KJ. Modeling schizophrenia using induced pluripotent stem cell-derived and fibroblastinduced neurons. Schizophr Bull. 2013;39:4-10.
46. Obokata H, Sasai Y, Niwa H, et al. Bidirectional developmental potential in reprogrammed cells with acquired pluripotency. Nature. 2014;505:676-680.
47. Obokata H, Wakayama T, Sasai Y, et al. Stimulus-Triggered fate conversion of somatic cells into pluripotency. Nature. 2014;505:641-647.
48. Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84-87.
49. Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science. 2014;343:80-84.
50. Deisseroth K. Circuit dynamics of adaptive and maladaptive behaviour. Nature. 2014;505:309-317.
51. Ripke S. World Congress of Psychiatric Genetics. Boston, MA; 2013.